THE latest results from a Phase II study highlight the potential of an all-oral combination therapy, featuring Bristol Myers Squibb's (BMS) cereblon E3 ubiquitin ligase modulator (CELMoD) mezigdomide and dexamethasone in treating triple-class-refractory multiple myeloma (MM).
Consequently, the sales of mezigdomide and iberdomide are expected to increase significantly, amid the shifting dynamics within the MM treatment market, forecasted GlobalData, an international data and analytics company.
According to GlobalData, the sales for mezigdomide and iberdomide are predicted to reach US$125m (A$195.7m) and US$389m (A$609m), respectively.
With Revlimid recently going off patent and sales expected to plummet, BMS hopes these therapies could take their place, but there is plenty of competition in the refractory MM space, GlobalData has reported.
Analyst at GlobalData Israel Stern said, "CELMoDs, including iberdomide, are more potent than the immunomodulatory drugs (IMiDS) Revlimid and Pomalyst, traditionally used in earlier lines of MM therapy".
"Mezigdomide is suited for patient's refractory to the IMiDS, many of whom also received prior therapies."
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 23
